All News

Bhavana “Tina” Bhatnagar, DO, reflects on AML’s transformation from few treatment options to targeted therapies and efforts to increase access to them.

Children of mothers with poor cardiovascular health during pregnancy had nearly double the risk of developmental delay at age 4.

The phase 3 SigVie-002 trial showed sigvotatug vedotin missed the OS end point, but the second-line subgroup showed a survival trend and manageable safety.

FDA approval of generic rifapentine introduces a new option for treating active tuberculosis and preventing progression of latent infection.

Patients with familial pulmonary fibrosis had faster FVC decline and were more likely to have a UIP pattern, supporting family history as a prognostic tool.

Structured CHE diagnosis improves outcomes: a multicenter CRF clarifies causes for most patients with chronic hand eczema, addressing diagnosis challenges and guiding targeted care.

Adults with obesity using an AI-CGM platform lost weight nearly 3 times faster during engaged vs nonengaged periods (1.17% vs 0.44% per week).

Real-world data show AI coaching plus CGM helps adults with obesity lose up to 7% in 6 months, with engagement driving faster weekly weight loss.

EXTEND trial data show nurse-delivered telehealth for type 2 diabetes missed its primary end point in fee-for-service care, raising questions about reimbursement.

New formulations make topical retinoids for acne vulgaris and scarring more tolerable and effective, with promising data for trifarotene, tretinoin combinations, and retinols for acne.

The 2 risks operate independently so that social interventions can reduce disease risk regardless of a patient’s genetic profile.

The 2026 conference, held in Baltimore, Maryland, offered expert insight into the past and future of sleep medicine.

Two abstracts from the 2026 ASCO annual meeting shed light on who is living with polycythemia vera in the US and what that experience is costing them.

Canadian dermatologists propose treat-to-target benchmarks for chronic hand eczema, pairing IGA-CHE and itch scores to guide therapy and follow-up.

Creatinine, not just a diabetes diagnosis, should trigger SGLT2 inhibitor use in CKD, says Sandra Chaparro, MD.

Resistance training, especially when paired with aerobic activity and limited TV time, was associated with the steepest reductions in type 2 diabetes risk.

Sheng Fu, MD, says the biggest barriers to managing heart failure, CKD, and obesity together aren't new drugs—they're broken transitions of care.

The FDA issued a CRL for cytisinicline's NDA over manufacturing deficiencies at a third-party facility, with no efficacy or safety concerns cited.

The message rate tripled, rising by 153% from 2020 to 2025, adding clinician workload and exposing equity gaps that managed care must address.

Community oncology practices are building bispecific programs in diverse configurations to retain patients and scale safely.

More short-term injections were needed to maintain visual outcomes in patients who lost their co-payment assistance.

Aficamten improved exercise capacity across submaximal, peak, and recovery measures.

These phase 3 studies are evaluating outcomes among patients living with polycythemia vera, myelofibrosis, and essential thrombocythemia.

Texas abortion ban worsens maternal mental health; SCD trials exclude 90% of adults; nutrition, hepatitis B, and cost-control gaps persist.

A new study finds Texas's abortion ban raised the likelihood of poor maternal mental health by 2.5 points—and 7 points for mothers on Medicaid.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

EHA 2026 highlights included practice-changing immunotherapy data in relapsed/refractory multiple myeloma and high-risk pediatric B-cell ALL, plus insights on childhood cancer predisposition.

Experts at ADA 2026 say nutrition guidelines must be personalized, culturally responsive, and built on research that reflects the patients they're meant to serve.